Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CV Incidence in Women Receiving Endocrine Therapy

JAMA Oncol; ePub 2016 Apr 21; Haque, Shi, et al

Publish date:: April 26, 2016

Women with breast cancer taking an aromatase inhibitor did not have more serious cardiovascular events than those using tamoxifen, according to a retrospective cohort study involving more than 13,000 individuals.

Investigators compared cardiovascular disease incidence in those receiving various endocrine therapies. Among the results:

• There were ~3,700 cardiovascular events.

• Those using aromatase inhibitors had a similar risk of cardiac ischemia and stroke as tamoxifen-only users.

• Those using aromatase inhibitors-only or sequentially after tamoxifen had a 26% higher risk of experiencing dysrhythmia, valvular dysfunction, and pericarditis.

• Tamoxifen and nonhormone users had an 18% higher risk of such.

Citation: Haque R, Shi J, Schottinger J, et al. Cardiovascular disease after aromatase inhibitor use. [Published online ahead of print April 21, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.0429.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,